Lantheus Holdings, Inc. (NASDAQ:LNTH) Position Increased by Tower Research Capital LLC TRC

Tower Research Capital LLC TRC lifted its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 6.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 5,178 shares of the medical equipment provider’s stock after acquiring an additional 309 shares during the period. Tower Research Capital LLC TRC’s holdings in Lantheus were worth $463,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. State of New Jersey Common Pension Fund D boosted its position in shares of Lantheus by 0.4% in the fourth quarter. State of New Jersey Common Pension Fund D now owns 26,428 shares of the medical equipment provider’s stock worth $2,364,000 after buying an additional 115 shares during the period. Bleakley Financial Group LLC lifted its position in Lantheus by 6.1% in the 4th quarter. Bleakley Financial Group LLC now owns 2,237 shares of the medical equipment provider’s stock worth $200,000 after buying an additional 129 shares in the last quarter. Avantax Advisory Services Inc. boosted its stake in shares of Lantheus by 5.9% during the 4th quarter. Avantax Advisory Services Inc. now owns 2,382 shares of the medical equipment provider’s stock valued at $213,000 after buying an additional 132 shares during the period. Foundry Partners LLC increased its stake in shares of Lantheus by 4.5% in the fourth quarter. Foundry Partners LLC now owns 3,103 shares of the medical equipment provider’s stock worth $278,000 after acquiring an additional 133 shares during the last quarter. Finally, UMB Bank n.a. raised its holdings in shares of Lantheus by 31.5% during the fourth quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock worth $50,000 after acquiring an additional 134 shares in the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

Insider Transactions at Lantheus

In other news, CFO Robert J. Jr. Marshall sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the sale, the chief financial officer now directly owns 113,860 shares in the company, valued at approximately $11,445,207.20. The trade was a 8.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Mary Anne Heino sold 53,107 shares of the company’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the transaction, the director now owns 440,399 shares of the company’s stock, valued at $41,551,645.65. The trade was a 10.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 63,109 shares of company stock worth $6,016,046. 1.50% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of brokerages have commented on LNTH. B. Riley lowered their target price on Lantheus from $127.00 to $122.00 and set a “buy” rating on the stock in a research note on Friday, March 21st. Truist Financial boosted their price target on Lantheus from $120.00 to $127.00 and gave the company a “buy” rating in a research note on Thursday, February 27th. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $112.00 price objective on shares of Lantheus in a research report on Tuesday, January 14th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $129.43.

Lantheus Trading Up 1.2 %

NASDAQ:LNTH opened at $103.96 on Wednesday. Lantheus Holdings, Inc. has a 1 year low of $65.89 and a 1 year high of $126.89. The firm’s fifty day simple moving average is $98.26 and its 200 day simple moving average is $95.14. The firm has a market capitalization of $7.12 billion, a PE ratio of 17.30 and a beta of 0.20.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The business had revenue of $391.11 million during the quarter, compared to the consensus estimate of $376.61 million. As a group, analysts anticipate that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.